Jeff Wrana

Last updated

Jeff Wrana
Born
Scarborough, Ontario, Canada
Awards Paul Marks Prize for Cancer Research (2005)
Academic background
EducationBSc, 1984, PhD, Biochemistry, 1991, University of Toronto
Thesis Regulation of connective tissue cells by transforming growth factor-[beta] (1991)

Jeffrey L. Wrana is a Canadian cancer researcher. He is the CIBC Breast Cancer Research Scientist and Mary Janigan Research Chair in Molecular Cancer Therapeutic at Mount Sinai Hospital and University of Toronto (U of T). As a Tier 1 Canada Research Chair in Medical Genetics and Microbiology at U of T, Wrana was elected a Fellow of the Royal Society of Canada.

Contents

Early life and education

Wrana is a native to Scarborough, Ontario, Canada. [1] He completed his Bachelor of Science degree at the University College, Toronto in 1984 [2] and his PhD in 1991 at the University of Toronto (U of T). [3] Following his PhD, Wrana completed his postdoctoral training at the Memorial Sloan Kettering Cancer Center from 1990 to 1995. [4] As a postdoctoral fellow, he wrote a seminal paper explaining how one signalling rogue molecule in cancers could communicate with other cells. [1]

Career

Following his postdoctoral fellowship, Wrana accepted a research position at Mount Sinai Hospital in Toronto. Working alongside Liliana Attisan, Wrana co-discovered that the mutation of the MADR2 gene was responsible for some forms of colon cancer. [5] Upon accepting a professorship position at his alma mater, Wrana began focusing on the transforming growth factor-beta (TGF-) family of cell signalling proteins that regulate cell growth and function. In his laboratory, Wrana helped to define the components of the TGF-ß signalling pathway and determine how its receptors are internalized by cells. [6] Beyond U of T, Wrana also continued to work as a Howard Hughes Medical Institute International Research Scholar. [7] Wrana's efforts were recognized with the 2005 Paul Marks Prize for Cancer Research by the Memorial Sloan-Kettering Cancer Center. [6] He was also awarded a seven-year Tier 1 Canada Research Chair (CRC) in Medical Genetics and Microbiology at U of T. [8] In his first year as a CRC, Wrana was elected a Fellow of the Royal Society of Canada's Division of Life Sciences. [9]

In 2009, Wrana and colleague Ian Taylor developed Dynamic Network Modularity (Dynemo), a biological model that could help physicians predict whether a woman is more likely to survive and recover from breast cancer: [10] [11] [12] it achieved this by analysing how proteins and other components within cancer cells interact with each other in order to form networks, [10] [13] [14] and how alterations of these processes could have an impact on tumorigenesis, [15] as well as the usage of specific drugs in oncological therapies. [13] [15] His efforts were recognised with the Premier's 2010 Summit Award for Medical Research. [16] Wrana later collaborated with Andras Nagy at Mount Sinai Hospital on a new stem cell project. After Nagy discovered a new method to create pluripotent stem cells without disrupting healthy genes, their laboratories discovered ways to improve the efficiency of stem cell creation for use in tissue regeneration. [17] In a mouse model of breast cancer, Wrana's research team also found that expression of the Cd81 protein in cancer-associated fibroblasts induced exosomal trafficking of Wnt11 to cancer cells, promoting metastasis through induction of the core planar cell polarity pathway. [18]

In 2015, Wrana was appointed the inaugural CIBC Scientist in Breast Cancer Research at the Lunenfeld-Tanenbaum Research Institute. [19] In this role, he began investigating how different cells contribute to gut development and maintenance. By 2018, Wrana and his postdoctoral fellow had co-discovered a new type of cell in the intestinal lining that they called the "revival stem cell". This new cell, which is only active for 24 hours, is responsible for creating new adult stem cells when the intestinal lining is damaged and functions to rebuild the intestinal lining. [20] [21] He was recognised with the 2018 McLaughlin Medal from the Royal Society of Canada for his "pivotal contributions to our understanding of biology, human diseases, and its treatment" and his leadership in the promotion of "Canadian science through collaborative research facilities and international impact." [22]

During the COVID-19 pandemic, Wrana used his laboratory and resources to assist in analysing thousands of COVID-19 tests across Ontario. In August 2020, his research team used the robotics platform to screen thousands of positive samples for variants by rapidly sequencing fingerprint regions of the viral genome to look for key mutations. [23] The following year, Wrana was a co-investigator in a project aimed at analysing 10,000 COVID-19 tests at once through C19-SPAR-Seq. [24]


Related Research Articles

<span class="mw-page-title-main">Memorial Sloan Kettering Cancer Center</span> Hospital in New York City, founded 1884

Memorial Sloan Kettering Cancer Center is a cancer treatment and research institution in Manhattan in New York City. It was founded in 1884 as the New York Cancer Hospital. MSKCC is one of 52 National Cancer Institute–designated Comprehensive Cancer Centers. It had already been renamed and relocated, to its present site, when the Sloan-Kettering Institute for Cancer Research was founded in 1945, and built adjacent to the hospital. The two medical entities formally coordinated their operations in 1960, and formally merged as a single entity in 1980. Its main campus is located at 1275 York Avenue between 67th and 68th Streets in Manhattan.

<span class="mw-page-title-main">Isadore Sharp</span> Canadian businessman

Isadore "Issy" Sharp, is a Canadian hotelier and writer. He is founder and chairman of Four Seasons Hotels and Resorts.

Tak Wah Mak, is a Canadian medical researcher, geneticist, oncologist, and biochemist. He first became widely known for his discovery of the T-cell receptor in 1983 and pioneering work in the genetics of immunology. In 1995, Mak published a landmark paper on the discovery of the function of the immune checkpoint protein CTLA-4, thus opening the path for immunotherapy/checkpoint inhibitors as a means of cancer treatment. Mak is also the founder of Agios Pharmaceuticals, whose lead compound, IDHIFA®, was approved by the FDA for acute myeloid leukemia in August 2017, becoming the first drug specifically targeting cancer metabolism to be used for cancer treatment. He has worked in a variety of areas including biochemistry, immunology, and cancer genetics.

<span class="mw-page-title-main">Icahn School of Medicine at Mount Sinai</span> American medical school

The Icahn School of Medicine at Mount Sinai, formerly the Mount Sinai School of Medicine, is a private medical school in New York City, New York, United States. The school is the academic teaching arm of the Mount Sinai Health System, which manages eight hospital campuses in the New York metropolitan area, including Mount Sinai Hospital and the New York Eye and Ear Infirmary.

<span class="mw-page-title-main">Lunenfeld-Tanenbaum Research Institute</span>

The Lunenfeld-Tanenbaum Research Institute is a medical research institute in Toronto, Ontario and part of the Sinai Health System. It was originally established in 1985 as the Samuel Lunenfeld Research Institute, the research arm of Mount Sinai Hospital, by an endowment from the Lunenfeld and Kunin families. It was renamed to the current name on June 24, 2013, after a $35 million donation from Larry and Judy Tanenbaum.

<span class="mw-page-title-main">José Baselga</span> Spanish oncologist (1959–2021)

Josep Baselga i Torres, known in Spanish as José Baselga, was a Spanish medical oncologist and researcher focused on the development of novel molecular targeted agents, with a special emphasis in breast cancer. Through his career he was associated with the Memorial Sloan Kettering Cancer Center, Vall d'Hebron Institute of Oncology, and the Massachusetts General Hospital in their hematology and oncology divisions. He led the development of the breast cancer treatment Herceptin, a monoclonal antibody, that targets the HER2 protein, which is impacted in aggressive breast cancers.

<span class="mw-page-title-main">Breast Cancer Research Foundation</span> Research organization

The Breast Cancer Research Foundation (BCRF) is an independent, not-for-profit organization which has raised $569.4 million to support clinical and translational research on breast cancer at medical institutions in the United States and abroad. BCRF currently funds over 255 researchers in 14 countries.

<span class="mw-page-title-main">Charlotte Friend</span> American virologist (1921–1987)

Charlotte Friend was an American virologist. She is best known for her discovery of the Friend leukemia virus. She helped to establish the concept of the oncovirus, studied the role of the host immune response in disease development, and helped define modern retrovirology.

Ming-Ming Zhou is an American scientist who focuses on structural and chemical biology, NMR spectroscopy, and drug design. He is the Dr. Harold, Golden Lamport Professor, and Chairman of the Department of Pharmacological Sciences. He is also the co-director of the Drug Discovery Institute at the Icahn School of Medicine at Mount Sinai and Mount Sinai Health System in New York City, as well as Professor of Sciences.

<span class="mw-page-title-main">Joan Massagué</span> Spanish biologist

Joan Massagué, is a Spanish biologist and the current director of the Sloan Kettering Institute at Memorial Sloan Kettering Cancer Center. He is also an internationally recognized leader in the study of both cancer metastasis and growth factors that regulate cell behavior, as well as a professor at the Weill Cornell Graduate School of Medical Sciences.

Simon N. Powell is a British cancer researcher and radiation oncologist residing in New York City.

<span class="mw-page-title-main">Kenneth Offit</span> American geneticist

Kenneth Offit is an American cancer geneticist and oncologist. He is currently Chief of the Clinical Genetics Service and the Robert and Kate Niehaus Chair in Inherited Cancer Genomics at Memorial Sloan Kettering Cancer Center. Offit is also a member of the Program in Cancer Biology and Genetics at the Sloan-Kettering Institute, Professor of Medicine and Healthcare Policy and Research at Weill Cornell Medical College, and a member of both the Board of Scientific Counselors of the National Cancer Institute and the Evaluation of Genomic Applications in Practice and Prevention working group of the U.S. Centers for Disease Control.

<span class="mw-page-title-main">Carlos Cordon-Cardo</span> Spanish-born American physician and scientist

Carlos Cordon-Cardo is a Spanish-born American physician and scientist known for his research in experimental pathology and molecular oncology. He holds the "Irene Heinz Given and John LaPorte Given" Chair in Pathology at Mount Sinai School of Medicine.

Marcel R.M. van den Brink is a Dutch oncologist and researcher at Memorial Sloan Kettering Cancer Center known for his research in hematopoietic stem cell transplantation for cancer patients.

Jeffrey Victor Ravetch is a professor and head of the Laboratory of Molecular Genetics and Immunology at The Rockefeller University.

<span class="mw-page-title-main">Alexander Rudensky</span>

Alexander Rudensky is an immunologist at Memorial Sloan Kettering Cancer Center known for his research on regulatory T cells and the transcription factor Foxp3.

Viviane Tabar is an American neurosurgeon, the Chair of the Department of Neurosurgery at Memorial Sloan Kettering Cancer Center in New York since 2017.

<span class="mw-page-title-main">Elisa Rush Port</span> American surgery professor

Elisa Rush Port FACS is Associate Professor of Surgery at the Icahn School of Medicine at Mount Sinai Hospital, as well as cofounder and director of the Dubin Breast Center at the Tisch Cancer Institute at Mount Sinai Health System, since 2010. She has received four research grants, has served as an investigator or co-investigator on 15 clinical trials, published 44 peer-reviewed articles, and published a total of 12 book chapters and books. She has specialized in sentinel-node biopsy, a diagnostic method that determines cancer stages based on spread to regional lymph nodes, nipple sparing mastectomy, and the use of MRI for breast cancer.

Maria Jasin is a developmental biologist at the Memorial Sloan Kettering Cancer Center. She is known for studying homologous recombination, a method in which double-strand breaks in DNA strands are repaired, and for discovering the role of BRCA1 and BRCA2 in cancers.

<span class="mw-page-title-main">Michel Sadelain</span>

Michel Sadelain is an genetic engineer and cell therapist at Memorial Sloan Kettering Cancer Center, New York, New York, where he holds the Steve and Barbara Friedman Chair. He is the founding director of the Center for Cell Engineering and the head of the Gene Transfer and Gene Expression Laboratory. He is a member of the department of medicine at Memorial Hospital and of the immunology program at the Sloan Kettering Institute. He is best known for his major contributions to T cell engineering and chimeric antigen receptor (CAR) therapy, an immunotherapy based on the genetic engineering of a patient's own T cells to treat cancer.

References

  1. 1 2 Ogilvie, Megan (March 7, 2009). "Our science superheroes: The xy-Men" (PDF). Toronto Star. Archived (PDF) from the original on April 16, 2023. Retrieved January 10, 2023.
  2. ↑ "Alumni of Influence: Jeff Wrana". University College, Toronto. Archived from the original on February 4, 2023. Retrieved January 10, 2023.
  3. ↑ "Dr. Jeffrey Wrana". University of Western Ontario. Archived from the original on February 4, 2023. Retrieved January 10, 2023.
  4. ↑ "Jeffrey L. Wrana, PhD". Memorial Sloan Kettering Cancer Center. Archived from the original on February 4, 2023. Retrieved January 10, 2023.
  5. ↑ "Gene tied to types of colon cancer". The Vancouver Sun. August 26, 1996. Archived from the original on February 4, 2023. Retrieved January 10, 2023– via newspapers.com.
  6. 1 2 "Young Investigators Celebrated at Award Ceremony". by the Memorial Sloan-Kettering Cancer Center. 2005. Archived from the original on February 4, 2023. Retrieved January 10, 2023.
  7. ↑ "The 2006 International Research Scholars from Canada and Latin America". Howard Hughes Medical Institute. November 1, 2006. Archived from the original on February 4, 2023. Retrieved January 10, 2023.
  8. ↑ Fraumeni, Paul (November 10, 2005). "U of T's Canada Research Chairs now at 206 13 new chairs announced". University of Toronto. Archived from the original on March 22, 2006. Retrieved January 10, 2023.
  9. ↑ "Symposium Celebrating New Fellows of the Royal Society of Canada". University of Toronto. 2007. Archived from the original on February 4, 2023. Retrieved January 10, 2023.
  10. 1 2 Taylor, Ian W.; Linding, Rune; Warde-Farley, David; Liu, Yongmei; Pesquita, Catia; Faria, Daniel; Bull, Shelley; Pawson, Tony; Morris, Quaid; Wrana, Jeffrey L. (February 1, 2009). "Dynamic modularity in protein interaction networks predicts breast cancer outcome". Nature Biotechnology. 27 (2): 199–204. doi:10.1038/nbt.1522. ISSN   1546-1696. PMID   19182785. S2CID   11594017. Archived from the original on March 18, 2023. Retrieved March 26, 2023.
  11. ↑ Yue, Rongting; Dutta, Abhishek (October 3, 2022). "Computational systems biology in disease modeling and control, review and perspectives". npj Systems Biology and Applications. 8 (1): 37. doi:10.1038/s41540-022-00247-4. ISSN   2056-7189. PMC   9528884 . PMID   36192551.
  12. ↑ Millar-Wilson, Andrew; Ward, Órla; Duffy, Eolann; Hardiman, Gary (October 26, 2022). "Multiscale modeling in the framework of biological systems and its potential for spaceflight biology studies". iScience. 25 (11): 105421. Bibcode:2022iSci...25j5421M. doi:10.1016/j.isci.2022.105421. ISSN   2589-0042. PMC   9663911 . PMID   36388986.
  13. 1 2 Ubelacker, Sheryl (February 1, 2009). "Researchers develop promising technology for breast cancer". Toronto Star. Archived from the original on February 4, 2023. Retrieved January 10, 2023.
  14. ↑ "New technology holds promise for predicting breast cancer recovery". CBC.ca . February 2, 2009. Archived from the original on March 18, 2023. Retrieved March 26, 2023.
  15. 1 2 Csermely, Peter; Korcsmáros, Tamás; Kiss, Huba J.M.; London, Gábor; Nussinov, Ruth (February 4, 2013). "Structure and dynamics of molecular networks: A novel paradigm of drug discovery: A comprehensive review". Pharmacology & Therapeutics. 138 (3): 333–408. doi:10.1016/j.pharmthera.2013.01.016. ISSN   0163-7258. PMC   3647006 . PMID   23384594.
  16. ↑ "Science at the Summit: $5 million Premier's Summit Awards go to leaders in stem cell and cancer research". May 19, 2010. Archived from the original on February 4, 2023. Retrieved February 3, 2023.
  17. ↑ "Scientists uncover important clues in the biology of stem cells". Lab Canada. August 12, 2010. Archived from the original on February 4, 2023. Retrieved February 3, 2023.
  18. ↑ Luga, Valbona; Zhang, Liang; Viloria-Petit, Alicia M.; Ogunjimi, Abiodun A.; Inanlou, Mohammad R.; Chiu, Elaine; Buchanan, Marguerite; Hosein, Abdel Nasser; Basik, Mark; Wrana, Jeffrey L. (December 21, 2012). "Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration". Cell. 151 (7): 1542–1556. doi: 10.1016/j.cell.2012.11.024 . ISSN   1097-4172. PMID   23260141.
  19. ↑ "Leading Mount Sinai researcher is the first CIBC Scientist in Breast Cancer Research". Mount Sinai Hospital. October 24, 2014. Archived from the original on February 4, 2023. Retrieved February 3, 2023.
  20. ↑ "Dr. Jeff Wrana and team follow a gut feeling and discover a new type of stem cell". Mount Sinai Hospital. April 24, 2019. Archived from the original on February 4, 2023. Retrieved February 3, 2023.
  21. ↑ Ayyaz, A.; Kumar, S.; Sangiorgi, B.; Ghoshal, B.; Gosio, J.; Ouladan, S.; Fink, M.; Barutcu, S.; Trcka, D.; Shen, J.; Chan, K.; Wrana, J. L.; Gregorieff, A. (April 24, 2019). "Single-cell transcriptomes of the regenerating intestine reveal a revival stem cell". Nature . 569 (7754): 121–125. Bibcode:2019Natur.569..121A. doi:10.1038/s41586-019-1154-y. PMID   31019301. S2CID   256770662. Archived from the original on February 4, 2023. Retrieved February 3, 2023.
  22. ↑ "Dr. Jeff Wrana awarded major prize for contributions to cancer research". Mount Sinai Hospital. September 18, 2018. Archived from the original on April 16, 2023. Retrieved February 3, 2023.
  23. ↑ Allen, Kate (August 10, 2020). "Can researchers find a way to run 10,000 COVID-19 tests at once? A team in Toronto is trying". Toronto Star. Archived from the original on February 4, 2023. Retrieved January 10, 2023.
  24. ↑ "Automated, next generation sequencing platform can accurately screen thousands for COVID-19". Mount Sinai Hospital. March 3, 2021. Archived from the original on February 4, 2023. Retrieved January 10, 2023.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.